+Compare
GILD
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
111.67B

GILD Price Prediction, Gilead Sciences AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
GILD Trading results, last 6 months
AI Robots NameP/L
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EST Dec 02, 2022

GILD in +1.37% Uptrend, advancing for three consecutive days on December 02, 2022

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GILD advanced for three days, in 146 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Aroon Indicator entered an Uptrend today. In of 205 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for GILD turned negative on November 18, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

GILD broke above its upper Bollinger Band on November 30, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.297) is normal, around the industry mean (5.359). P/E Ratio (33.670) is within average values for comparable stocks, (33.666). Projected Growth (PEG Ratio) (0.712) is also within normal values, averaging (4.326). Dividend Yield (0.033) settles around the average of (0.026) among similar stocks. P/S Ratio (4.137) is also within normal values, averaging (4.166).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

GILD is expected to report earnings to fall 21.05% to $1.50 per share on February 07

Gilead Sciences GILD Stock Earnings Reports
Q4'22
Est.
$1.50
Q3'22
Beat
by $0.38
Q2'22
Beat
by $0.06
Q1'22
Beat
by $0.32
Q4'21
Missed
by $0.90
The last earnings report on October 27 showed earnings per share of $1.90, beating the estimate of $1.52. With 971.22K shares outstanding, the current market capitalization sits at 111.67B.
AI
A.I.Advisor
published Dividends

GILD is expected to pay dividends on December 29, 2022

Gilead Sciences GILD Stock Dividends
A dividend of $0.73 per share will be paid with a record date of December 29, 2022, and an ex-dividend date of December 14, 2022. The last dividend of $0.73 was paid on September 29. Read more...
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Johnson & Johnson (NYSE:JNJ), Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Pfizer (NYSE:PFE), Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 82.09B. The market cap for tickers in the group ranges from 226K to 467.68B. JNJ holds the highest valuation in this group at 467.68B. The lowest valued company is NEWG at 226K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 2%. For the same Industry, the average monthly price growth was 8%, and the average quarterly price growth was -0%. HZNP experienced the highest price growth at 34%, while MAYNF experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 114%. For the same stocks of the Industry, the average monthly volume growth was -29% and the average quarterly volume growth was 2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 25
P/E Growth Rating: 48
Price Growth Rating: 46
SMR Rating: 44
Profit Risk Rating: 59
Seasonality Score: 23 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I. Advisor
published General Information

General Information

a developer of therapeutic products and treatments for life threatening diseases

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
333 Lakeside Drive
Phone
+1 650 574-3000
Employees
13600
Web
https://www.gilead.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VUZI4.520.22
+5.12%
Vuzix Corp
DXCM118.111.83
+1.57%
DexCom
ERF18.140.22
+1.23%
Enerplus Corp
FRSX0.66-0.01
-1.47%
Foresight Autonomous Holdings Ltd
SNCY19.37-0.83
-4.11%
Sun Country Airlines Holdings

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with AMGN. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+1.29%
AMGN - GILD
51%
Loosely correlated
-0.31%
JNJ - GILD
44%
Loosely correlated
+0.08%
NVS - GILD
44%
Loosely correlated
+0.19%
BMY - GILD
42%
Loosely correlated
+0.31%
PFE - GILD
42%
Loosely correlated
-0.33%
More